Vilket är priset för Impact Therap-b (7630)

Priset för Impact Therap-b (7630) är $1.85

Vilket är marknadsvärdet för Impact Therap-b (7630)

Marknadsvärdet för Impact Therap-b (7630) är $510.85M

Impact Therap-b (7630) Rörelsemarginal

IMPACT Therapeutics, a biotechnology firm, specializes in the discovery and advancement of precision anti-cancer treatments rooted in synthetic lethality, operating across China and international markets. The company's primary offering, Senaparib (IMP4297), is a PARP1/2 inhibitor currently deployed as a first-line maintenance therapy for ovarian cancer. Beyond this, Impact Therapeutics maintains a robust pipeline of investigational drugs. This includes IMP1734, a next-generation PARP1 selective inhibitor undergoing Phase I/II trials as a standalone treatment for advanced solid tumors. Another promising candidate is IMP9064, an ATR kinase selective inhibitor, also in Phase I/II clinical studies for advanced solid tumors as a monotherapy. IMP1707, a PARP1 selective inhibitor capable of penetrating the central nervous system, is in Phase I development for homologous recombination repair-deficient tumors. Additionally, IMP7068, an advanced WEE1 inhibitor, is progressing through Phase I/II clinical trials for various advanced solid tumors. Furthermore, a range of other compounds, namely IMP22, IMP25, IMP08, IMP13, IMP10, IMP27, and IMP32, are in the preclinical development phase. The company, established in 2009, is headquartered in Shanghai, China.

År	Rörelsemarginal	Ändra
Inte tillräckligt med data för de angivna datumen.

År

Rörelsemarginal

Ändra

Inte tillräckligt med data för de angivna datumen.

Företag	Rörelsemarginal	Skillnad i rörelsemarginal	Land
Eli Lilly and Company LLY.US	43.92%	-	US
Johnson & Johnson JNJ.US	26.81%	-	US
AbbVie Inc. ABBV.US	29.32%	-	US
Roche Holding AG RO.SW	26.59%	-	CH
Merck & Co., Inc. MRK.US	16.65%	-	US

Företag

Rörelsemarginal

Skillnad i rörelsemarginal

Land